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Mechanism of differential Zika and dengue virus
neutralization by a public antibody lineage targeting
the DIII lateral ridge
Haiyan Zhao1, Lily Xu1, Robin Bombardi2, Rachel Nargi2, Zengqin Deng3, John M. Errico1, Christopher A. Nelson1, Kimberly A. Dowd4,
Theodore C. Pierson4, James E. Crowe Jr.2,8,9, Michael S. Diamond1,5,6, and Daved H. Fremont1,5,7
We previously generated a panel of human monoclonal antibodies (mAbs) against Zika virus (ZIKV) and identified one, ZIKV-
116, that shares germline usage with mAbs identified in multiple donors. Here we show that ZIKV-116 interferes with ZIKV
infection at a post-cellular attachment step by blocking viral fusion with host membranes. ZIKV-116 recognizes the lateral
ridge of envelope protein domain III, with one critical residue varying between the Asian and African strains responsible for
differential binding affinity and neutralization potency (E393D). ZIKV-116 also binds to and cross-neutralizes some dengue virus
serotype 1 (DENV1) strains, with genotype-dependent inhibition explained by variation in a domain II residue (R204K) that
potentially modulates exposure of the distally located, partially cryptic epitope. The V-J reverted germline configuration of
ZIKV-116 preferentially binds to and neutralizes an Asian ZIKV strain, suggesting that this epitope may optimally induce related
B cell clonotypes. Overall, these studies provide a structural and molecular mechanism for a cross-reactive mAb that uniquely
neutralizes ZIKV and DENV1.
Introduction
Zika virus (ZIKV) typically causes a self-limiting febrile illness,
with most infected individuals exhibiting minimal or no
symptoms (Duffy et al., 2009). However, ZIKV infection can
result in severe neurological disease (Mlakar et al., 2016), in-
cluding neurodevelopmental defects in infants after congenital
infection (Moore et al., 2017; de Paula Freitas et al., 2016).
Dengue virus (DENV) is genetically related to ZIKV, infects
nearly 400 million people annually, and causes variable clinical
disease ranging from a mild to severe febrile illness and life-
threatening dengue shock syndrome (Bhatt et al., 2013). Since
its introduction and spread in the Western hemisphere in
2015–2016, ZIKV has emerged as a significant global health
concern.
Both ZIKV and DENV are principally transmitted by mos-
quitoes (Cao-Lormeau et al., 2016) and belong to the Flavivirus
genus of the Flaviviridae family of single-stranded positive-
sense RNA viruses, which also include West Nile (WNV), Japa-
nese encephalitis (JEV), yellow fever, and the tick-borne
encephalitis viruses (Lazear and Diamond, 2016). Flavivirus
genomes encode a single polyprotein that is cleaved by viral
and cellular proteases into three structural proteins (capsid
protein, precursor membrane protein, and envelope [E] pro-
tein) and seven nonstructural proteins. Cryo-electron mi-
croscopy (cryo-EM) models of mature flaviviruses show
90 anti-parallel E protein dimers lying flat against the virion
surface with T = 3 quasi-icosahedral symmetry (Zhang et al.,
2013; Kostyuchenko et al., 2016; Qiu et al., 2018). E protein is
the primary target of neutralizing antibodies and is composed
of three ectodomains: domain I (DI), which links DII and DIII
together; DII, which contains a fusion loop that mediates viral
fusion with host endosomes; and DIII, which adopts an Ig-like
fold that undergoes a substantial repositioning during viral
fusion (Rey et al., 1995; Dai et al., 2016; Modis et al., 2004).
Antibodies against flaviviruses map to epitopes in all three
domains, and those against DIII are among the most potent at
neutralizing infection (Nybakken et al., 2005; Robbiani et al.,
2017; Zhao et al., 2016; Shrestha et al., 2010; Sukupolvi-Petty
et al., 2010).
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While the affinity of antibody binding governs the proportion
of epitopes occupied under steady state conditions (Robinson
et al., 2015), it does not always correlate with flavivirus neutrali-
zation. Another factor that influences antibody neutralization is
the valency of virion engagement, where potent neutralization
can be obtained for a bivalent binding antibody even in the setting
of relatively weak monovalent affinity (Edeling et al., 2014). A
third important factor is epitope accessibility, which is influenced
by virion maturation as well as the capacity for dynamic motion
and affects the stoichiometry of antibody binding and efficiency of
neutralization (Pierson et al., 2007; Pierson and Diamond, 2012).
Germline selection and affinity maturation of broadly neu-
tralizing mAbs have been studied extensively for HIV and influ-
enza virus and have allowed for the development of novel vaccine
strategies (Pappas et al., 2014; Liao et al., 2013; Duan et al., 2018).
Germline precursors generally showweak or undetectable affinity
for target immunogens; thus, vaccine antigens may need to be
engineered to induce neutralizing antibodies. For flaviviruses,
most cross-reactive mAbs against the E protein target the highly
conserved fusion loop in DII. The accessibility of the fusion loop is
dependent on the maturation state of the virus, with limited ex-
posure on mature virions, and most fusion loop–directed mAbs
exhibit weak neutralization potency (Zhao et al., 2016; Cherrier
et al., 2009; Rey et al., 2018). Another group of cross-reactive
mAbs has also been identified from DENV-infected donors that
bind a quaternary E-dimer epitope and can neutralize both DENV
and ZIKV infection efficiently (Dejnirattisai et al., 2015; Fernandez
et al., 2017). These E-dimer epitope mAbs have shown significant
potency against ZIKV both prophylactically and therapeutically in
murine models of infection (Fernandez et al., 2017).
We and others have reported mAbs from multiple human
donors that all use the VH3–23 heavy chain and VK1–5 light chain
and have the unique capacity to neutralize both ZIKV and DENV1
with varying potencies (Sapparapu et al., 2016; Robbiani et al.,
2017; Magnani et al., 2017; Niu et al., 2019). Several of these
public lineage mAbs have demonstrated protection in animal
models of ZIKV challenge. Herein, we combine virological and
biophysical assays to define the mechanistic basis for the neu-
tralizing activity of ZIKV-116, a mAb derived from a donor in-
fected by ZIKV in 2015 in Brazil. Functional studies in cell culture
show that ZIKV-116 primarily inhibits infection at a post-cellular
attachment step by blocking viral fusion with host membranes.
X-ray crystallographic studies reveal that ZIKV-116 recognizes a
DIII lateral ridge (LR) epitope, with one residue distinguishing
binding and consequent neutralization of Asian versus African
ZIKV strains. ZIKV-116 also potently neutralizes infection of
DENV1, with genotype-specific neutralization best explained by
differential epitope exposure. Lastly, we constructed the inferred
V-J germline sequence of ZIKV-116 and demonstrated that it
binds and neutralizes diverse ZIKV and DENV1 strains, albeit
with lower potency than the affinity-matured clone.
Results
ZIKV-116 primarily inhibits infection at a post-attachment step
To investigate how ZIKV-116 inhibited virus infection, we per-
formed pre- and post-attachment neutralization assays with a
French Polynesian ZIKV strain (H/PF/2013). As anticipated,
prebinding with ZIKV-116 efficiently limited ZIKV infection
(Fig. 1 A). ZIKV-116 similarly inhibited ZIKV infection after virus
was bound to the target cell surface (half maximal inhibition
concentration [IC50] of 52 and 105 ng/ml for pre- and post-
attachment neutralization, respectively). To corroborate these
studies, we evaluated whether ZIKV-116 could inhibit cellular
attachment of ZIKV. Different concentrations of ZIKV-116 or an
isotype control mAb were preincubated with ZIKV and then
added to Vero cells. After extensive washing, cell-associated
viral RNA was measured by quantitative real-time PCR (qRT-
PCR). ZIKV-116 did not block virus attachment relative to isotype
control near the IC50 of 0.1 µg/ml (Fig. 1 B). However, a modest
inhibition of attachment (∼60%) was observed at concentrations
∼10- to 100-fold higher than the IC50 value, suggesting that at-
tachment blockade is not the dominant inhibitory mechanism of
ZIKV-116.
ZIKV-116 can block viral fusion with host membranes
We next examined whether ZIKV-116 could block viral fusion.
Normally, flaviviruses enter cells via receptor-mediated inter-
nalization, and pH-triggered fusion occurs with endosomal
membranes (Modis et al., 2004). However, under low-pH con-
ditions, cell-associated virus can be induced to fuse at the plasma
membrane, a process termed “fusion from without” (Edwards
and Brown, 1986; Liao and Kielian, 2005; Thompson et al., 2009;
Fernandez et al., 2018). ZIKV was preadsorbed to Vero cells on
ice and subsequently treated with ZIKV-116 or control ZV-2, a
ZIKV-specific nonneutralizing mAb (Zhao et al., 2016). Virus-
plasma membrane fusion was triggered by a brief exposure to
low pH, and infection was monitored at 24 h after initial treat-
ment. In all steps, 25 mM NH4Cl was added to prevent ZIKV
entry and infection via endosomal fusion (Helenius et al., 1982).
As expected, under neutral pH conditions, ZIKV infection was
rarely detected. In comparison, exposure of cell-adsorbed ZIKV
to pH 5.8 resulted in a 10-fold increase in infection. ZIKV-116
completely blocked this pH-triggered infection, whereas mAb
ZV-2 did not (Fig. 1, C and D).
To block fusion in cells, ZIKV-116 must retain binding at the
acidic pH of the endosome. To evaluate this question, we per-
formed biolayer interferometry (BLI) with ZIKV-116 and its
ligand ZIKV DIII at pH values corresponding to the extracellular
and endosomal milieu. ZIKV-116 was immobilized and dipped
into solutions of recombinant ZIKV DIII (H/PF/2013) ranging
from 3.125 nM to 100 nM concentration. At pH 7.4, DIII bound to
ZIKV-116 with a kinetically derived binding affinity (KD) of 1.15
nM and t1/2 of 25.70 min. The complex was only slightly less
stable at pH 5.5, with a KD of 2.24 nM and t1/2 of 16.06 min (Fig. 1,
E and F). These results suggest that ZIKV-116 engagement of
virions should endure within the acidic environment of endo-
somes such that viral fusion can be blocked.
X-ray crystal structure of ZIKV-116 in complex with ZIKV DIII
To better understand ZIKV-116–mediated neutralization, we
determined the x-ray crystal structure of ZIKV-116 antigen-
binding fragments (Fab) in complex with ZIKV DIII (H/PF/
2013) at 2.3 Å resolution (Fig. 2 and Table S1). ZIKV-116 binds to
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the LR of DIII by engaging the N-terminal region as well as the
BC-, CC9-, and FG-loops. The total buried surface area at the
antibody-antigen interface is 1,551 Å2, with a shape comple-
mentarity factor of 0.71. The heavy chain accounts for 67% of the
interface, with a combined buried surface of 1,042 Å2 (542 Å2 on
DIII and 500 Å2 on the heavy chain), and the light chain con-
tributes the remaining buried surface area (264 Å2 on DIII and
245 Å2 on the light chain). The interaction is mediated by con-
tacts between 12 DIII residues and residues from 5 ZIKV-116
complementarity-determining regions (CDRs: (CDR-H1, CDR-
H2, CDR-H3, CDR-L1, and CDR-L3) plus 2 VH framework resi-
dues. Two of the DIII residues (TE309 and KE394) are contacted by
both heavy and light chains. Binding of ZIKV-116 to DIII is me-
diated by 11 direct hydrogen bonds and 9 water-mediated net-
works in addition to van derWaals contacts. The N-terminal and
FG-loop regions contain the majority of the interactions (79 of 99
contacts) with ZIKV-116. The FG-loop has the most extensive
contact network, forming five direct hydrogen bonds and four
water-mediated hydrogen bonds with ZIKV-116. The N-terminal
region of DIII contributes 35 contacts and forms 5 additional
direct hydrogen bonds with residues from the CDR-L3 and CDR-
H2 of ZIKV-116 (Tables S2–S6). We note that there are two
complexes in the crystallographic asymmetric unit that adopt
overall similar conformations, with a root mean square
Figure 1. The mechanistic basis of ZIKV-116 neutralization. (A) Pre-/post-attachment inhibition assay. Serial dilutions of mAb were added to the Vero cells
before (pre, black line) or after (post, red line) virus adsorption to the cells, and infection was determined by FFA. Wells containing mAb were compared with
wells containing no mAb to determine the relative infection. (B) Attachment blockade assay. ZIKV (H/PF/2013) was incubated with ZIKV-116 or isotype control
(human IgG1) for 1 h, followed by addition to pre-chilled Vero cells for 1 h. Bound ZIKV RNA was measured by qRT-PCR. GAPDH was used for an internal
control, and viral RNA fold change was compared with control cells incubated in the absence of mAb. Data are the mean of three independent experiments
performed in duplicate or quadruplicate. Error bars indicate SD. (C and D) Fusion blockade assay. Pre-chilled Vero cells were incubated with ZIKV (multiplicity
of infection of 80) for 1 h on ice. Subsequently, 100 µg/ml of ZIKV-116 IgG, control ZV-2 IgG (nonneutralizing anti-ZIKV mAb), or medium was added for 1 h on
ice, and the pH was shifted to 5.8 to trigger virus fusion with plasma membrane. After pH normalization, cells were incubated at 37°C for 24 h, and the number
of infected cells was determined by flow cytometry. 25 mM NH4Cl was included in the medium throughout the procedure. Representative flow cytometric
histogram (C). The data averaged from two independent experiments are shown as means with SD (D). (E and F) Representative BLI profile of ZIKV-116 to
recombinant H/PF/2013 DIII at neutral (pH 7.4) and acidic pH (pH 5.5). The experimental curves (black lines) were fitted using a 1:1 Langmuir binding analysis
(red lines), and the results are representative of three independent experiments. Statistical significance was determined by two-tailed t test (D) or two-way
ANOVA with Sidak’s post-test (B). ****, P < 0.0001.
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deviation of 1.19 Å over 332 Cα atoms of DIII and variable do-
mains of ZIKV-116 (Fig. S1, A and B). However, presumably due
to crystal packing, we observed a different conformation of the
DIII CC9-loop in one complex where it is not engaged by ZIKV-
116 CDR loops but rather by an adjacent Fab (Fig. S1, C and D).
Variation at residue 393 modulates the binding kinetics of
ZIKV-116 to DIII
Weperformed infection assays and found that ZIKV-116 neutralized
four ZIKV Asian strains (H/PF/2013, Brazil Fortaleza, Cambo-
dia_FSS13025, and Puerto Rico_PRVABC58) more effectively than
two African strains (MR-766 and Dakar 41519; Table S7), consistent
with our previous observations (Sapparapu et al., 2016). Sequence
analysis of the ZIKV-116 structural epitope among the seven rep-
resentative ZIKV strains showed that 11 out of 12 contact residues
are invariant. However, African strains (MR-766 and Dakar 41519)
have an Asp at residue 393, while most Asian strains have a Glu.
Interestingly, one Asian strain (Malaysia_P6740), which has an
Asp393 like African strains, was less effectively neutralized by ZIKV-
116 compared with other Asian strains (Table S7).
In our structure, Glu393 is directly contacted by ZIKV-116
CDR-H3 and participates in an extensive hydrogen-bonding
network, forming three direct hydrogen bonds and two water-
mediated indirect hydrogen bonds with ZIKV-116 (Fig. 3 A and
Tables S4–S6). To explore whether the residue 393 impacts
ZIKV-116 activity, we used BLI to compare the binding of ZIKV-
116 to different purified DIII proteins, including WT H/PF/2013
DIII, E393D H/PF/2013 DIII, andWTMR-766 DIII. ZIKV-116 bound
MR-766 DIII weakly (100-fold higher KD [121 nM] and t1/2 of
0.25 min) compared with H/PF/2013 DIII (Fig. 3, B and C; and
Fig. 1 E). Correspondingly, the E393D substitution of H/PF/2013
DIII (to the residue in MR-766) significantly decreased the
binding affinity and half-life, with a KD of 62 nM and t1/2 of 0.52
min. Thus, it appears that a single methyl group of residue 393 in
ZIKV strains can determine ZIKV-116 binding strength, most
likely because the shorter side chain is incapable of optimally
forming a hydrogen-bonding network with residues in CDR-H3,
specifically ArgH96 and GluH100C, which engage the DIII Glu393
carboxylate and main chain, respectively (Fig. 3 A).
The amount of ZIKV-116 required to neutralize Malaysia_P6740
strain is higher than that required to inhibit Asian strain H/PF/
2013, and lower than the amount required to neutralize African
strains (Table S7). Consistently, the DIIIFP(E393D) mutant, which is
identical to the naturally occurring DIII of Malaysia_P6740 strain,
bound ZIKV-116 with an ∼50-fold lower affinity than DIIIFP and
∼2-fold higher affinity than WT DIIIMR. While the structurally
defined epitope is strictly conserved among analyzed ZIKV strains
with the exception of residue 393, the AfricanMR-766 strain varies
at three additional positions in DIII regions that could distally affect
the epitope and thereby mAb binding (Fig. S2).
Variation at residue 393 modulates the neutralizing activity of
ZIKV-116 against different ZIKV strains
To assess the role of residue 393 in differential ZIKV-116 neu-
tralization, we generated ZIKV reporter virus particles (RVPs)
with H/PF/2013 and MR-766 structural proteins and incorporated
Figure 2. ZIKV-116 in complex with ZIKV H/PF/2013 DIII. (A) Ribbon diagram of the crystal structure, with DIII colored in sky blue, heavy chain in magenta,
and light chain in pink. (B) Surface model of ZIKV DIII (left) and ZIKV-116 Fab (right) showing the interface of the complex. DIII contacts are displayed by heavy
chain (magenta), light chain (pink), or both chains (cyan). Fab contacts are highlighted in magenta for heavy chain and pink for light chain. (C) The structural
epitope on ZIKV DIII contacted by the ZIKV-116 is shown as sticks and colored as in B. (D) ZIKV-116 contacts on the four segments of DIII amino acid sequence
alignment of different ZIKV strains. The DIII residues that make van der Waals contact distance <3.90 Å are colored as in B, and the numbers below the H/PF/
2013 DIII represent the total number of contacts for each residue. Asian genotype: French Polynesia_H/PF/2013, Brazil_Fortaleza, Cambodia_FSS13025, Puerto
Rico_PRVABC58, Malaysia_P6740; African genotype: Senegal_Dakar 41519, Uganda_MR-766. VH, heavy chain variable domain; VL, light chain variable domain.
Zhao et al. Journal of Experimental Medicine 4
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the reciprocal changes at residue 393. Exchanging the amino
acid at residue 393 dramatically reversed the ZIKV-116 neu-
tralization phenotype between the H/PF/2013 and MR-766
strains. The IC50 values of WT H/PF/2013 and E393D variant
increased from 69 to 4,855 ng/ml, making the neutralization of
E393D H/PF/2013 RVPs similar to the neutralization of WT MR-
766. Reciprocally, D393E MR-766 RVPs were neutralized by
ZIKV-116 similarly to WT H/PF/2013 RVPs (approximately
twofold difference in IC50; Fig. 3 D). In comparison, the pres-
ence of D393 or E393 had little effect on mAb ZV-67, which binds
an overlapping DIII-LR epitope and neutralizes H/PF/2013 and
MR-766 strains equivalently (Fig. 3 E; Zhao et al., 2016). Taken
together with our binding studies, these observations strongly
suggest that differential ZIKV neutralization by ZIKV-116 is
primarily controlled by residue 393 variation, and that mAb-
binding affinity correlates well with neutralization potency
against distinct ZIKV strains.
Differential neutralization of DENV1 genotypes
Sequence analysis of the ZIKV-116 mAb showed that it used the
VH3–23 heavy chain and VK1–5 light chain genes, and VH3–23/
VK1–5mAbs against ZIKV have been reported to cross-react with
DENV1 (Sapparapu et al., 2016; Robbiani et al., 2017; Magnani
et al., 2017; Niu et al., 2019). To investigate cross-reactivity, we
tested the specificity of ZIKV-116 against a panel of recombinant
proteins from different flaviviruses by ELISA (Fig. 4, A and B). In
this qualitative assay, ZIKV-116 recognized H/PF/2013 DIII, E,
and E-FL (a fusion loop mutant) equally well as MR-766 DIII. We
also found that ZIKV-116 can recognize DIII from DENV1, but not
DIII from other DENV serotypes (DENV2, DENV3, or DENV4) or
E or DIII proteins from other flaviviruses (WNV, JEV, Spond-
weni, or Powassan viruses). Based on these binding properties,
we assessed whether ZIKV-116 could inhibit infection of differ-
ent DENV1 strains. We found that ZIKV-116 neutralized a DENV1
genotype 2 strain (16007) more effectively than a genotype 4
strain (West Pac-74), with IC50 values of 11 and 73 ng/ml, re-
spectively (Fig. 4 C). No neutralization activity was observed to
DENV2. Sequence comparison revealed only two amino acid
differences in DIII between 16007 and West Pac-74, both located
in the CC9-loop (T339S and A345V). Residue 345 but not 339 is
located within the predicted ZIKV-116 footprint on DENV1 DIII
(Fig. 5 A and Fig. S2).
A residue distal to the ZIKV-116 epitope modulates DENV1
strain neutralization sensitivity
Since ZIKV-116 less efficiently neutralized DENV1 West Pac-74
than 16007, we evaluated the binding affinity of ZIKV-116 to DIII
from these two viruses. BLI experiments revealed that ZIKV-116
Figure 3. Variation at residue 393 in the ZIKV-116 epitope is responsible for the neutralization differences between two ZIKV strains. (A) Detailed
interactions of DIII residues EE393 and KE394 with ZIKV-116, with 2Fo-Fc electron density map (1.5 σ) colored in pale cyan. The water molecules are shown as
spheres and colored in red, and the hydrogen bonds are marked as black dashed lines. (B and C) Comparison of KD and t1/2 of ZIKV-116 to DIII from H/PF/2013
(FP), MR-766 (MR), and FP bearing E393D mutation. The results show the average of at least two independent experiments. Error bars indicate SD. (D and E)
Neutralization profiles of mAbs against WT and mutant ZIKV FP and MR RVPs containing reciprocal amino acid substitutions at residue 393 (left). IC50 values
from at least three independent experiments performed in duplicate (right). ZV-67 (another ZIKV DIII-LR mAb) served as a control mAb. Serial dilutions of mAbs
were incubated with RVPs for 1 h at 37°C, followed by infection of Raji-DCSIGNR cells. GFP-positive, infected cells were determined by flow cytometry at 40 h.
Statistical significance was determined by one-way ANOVA with a Tukey’s test (B and C) or two-tailed t tests (D and E). ns, not significant; *, P < 0.05; **, P <
0.01; ***, P < 0.001; ****, P < 0.0001.
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bound DIII from the two strains with nearly identical affinities
and kinetics, with a KD of 10.7 nM and t1/2 of 6.1 min for DIII16007
versus a KD of 13.2 nM and t1/2 of 6.2 min for DIIIWest Pac-74 (Fig. 5,
B and C); these data are consistent with the complete conser-
vation of the predicted ZIKV-116 epitope on DENV1 besides the
identified A345V variation (Fig. S2). We previously reported a
DENV1-specific mAb that recognizes a cryptic epitope in DIII and
exhibited genotypic differences in neutralization, DENV1-E111
(Austin et al., 2012; Fig. 4 C). Dowd et al. (2015) went on to
discover that a DII residue distal from the epitope (residue 204;
Fig. 5, A and E) altered DENV1-E111 neutralization, perhaps by
changing the display of the DIII epitope in a genotype-dependent
manner. To investigate whether this same residue 204 variation
also accounts for the different neutralization activity of ZIKV-
116, we performed neutralization assays using DENV1 16007 and
West Pac-74 RVPs bearing reciprocal changes at E residue 204.
Exchange of K204R on the West Pac-74 background shifted the
neutralization curves to that seen with WT 16007 RVPs (IC50 of
29 ng/ml for K204R West Pac-74 versus 16 ng/ml for WT 16007).
Reciprocally, exchange of R204K on the 16007 background led to
an 11-fold reduced ZIKV-116 neutralization potency (Fig. 5 D). In
contrast, a control mAb, WNV-E60, which binds the E-FL epi-
tope in DII, showed similar neutralization potency with all WT
and variant DENV1 RVPs (Fig. 5 F).
A reverted, unmutated ancestor form of ZIKV-116 is capable of
binding and neutralizing ZIKV and DENV1 strains
The affinity-matured ZIKV-116 is encoded by VH3–23 and VK1–5
germline genes, with 18 aa substitutions in the VH domain and 10
aa substitutions in the VL domain. Only 2 of the 28 residues
mutated from V and J gene segments are part of the ZIKV-116
paratope, SH31N in CDR-H1 and TH57K adjacent to CDR-H2, and
both residues make only modest contacts with the DIII-LR epi-
tope (Tables S2–S6). The remaining 26 residue substitutions are
located mainly in the VH framework regions, CDR-H2 and CDR-
L1/2 (Fig. 6, A and B). To investigate the properties of the ZIKV-
116 clonal lineage, we reverted ZIKV-116 to the inferred germline
sequence (reverted, unmutated ancestor mAb, ZIKV-116-V.J.Rev)
and produced it using the same IgG1 expression vectors as the
affinity-matured mAb. Both the V and J gene segments were
reverted to the respective templated germline sequences. The
reverted antibody retained the original CDR-H3 of the mature
WT ZIKV-116 antibody, which possesses one somatically mutated
residue when compared with the inferred germline D gene
segment IGHD3-10*01.
We next evaluated the binding of ZIKV and DENV1 DIII
proteins to immobilized ZIKV-116-V.J.Rev using BLI (Fig. 6 C).
Surprisingly, ZIKV-116-V.J.Rev showed only a moderately de-
creased binding to ZIKVH/PF/2013 DIII (KD of 48.9 nM and t1/2 of
1.18 min). On the other hand, binding to DIII from ZIKV MR-766
and the two DENV1 strains was markedly weaker (KD of ∼10 µM
for DIIIMR-766 and KD of ∼7 µM for DIII16007 and DIIIWest Pac-74).
The decreased binding to DIII of all four viruses was due pri-
marily to increased dissociation rates (Fig. 6 C and Table S8).
Neutralization assays revealed that ZIKV-116-V.J.Rev has
potent activity against ZIKV H/PF/2013, only a sevenfold de-
crease comparedwith ZIKV-116 (Fig. 6 D). The V-J–revertedmAb
was also capable of neutralizing the two DENV1 strains, albeit
Figure 4. ZIKV-116 neutralizes DENV1 strain 16007
better thanWest Pac-74. (A) ZIKV-116 or control mAbs
(WNV-E111 [flavivirus cross-reactive] and DENV4-E88
[DENV4 type-specific]) were tested for binding to the
indicated flavivirus proteins (ZIKV E, ZIKV E-FL [mutant
strain of H/PF/2013], ZIKV DIII [strains of H/PF/2013
and MR-766], WNV E and DIII, SPOV E [Spondweni vi-
rus], and DENV1–4 DIII) as indicated in ELISA. (B) ZIKV-
116 or control mAbs (JEV-106 [JEV DIII-specific] and
POWV-61 [Powassan DIII-specific]) were tested for
binding to the indicated DIII of ZIKV H/PF/2013, JEV, and
POWV. The results are representative of two indepen-
dent experiments performed in triplicate. (C) Neutrali-
zation curves of DENV2 (D2S20) and DENV1 (16007 and
West Pac-74 [WP]) by ZIKV-116 and control mAb
DENV1-E111. The indicated virus was incubated with
serial-diluted mAbs for 1 h at 37°C followed by addition
of the mixture to Vero cells. Then, FRNT assays were
performed, and the percentage of infection was calcu-
lated by comparing to no mAb–treated wells. Data were
pooled from two or more independent experiments
performed in triplicate or quadruplicate.
Zhao et al. Journal of Experimental Medicine 6
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with 30- to 50-fold lower activity compared with the somatically
mutated mAb. However, ZIKV-116-V.J.Rev neutralization of
ZIKV MR-766 was only modest, with an apparent 100-fold re-
duced activity that failed to block infection of 50% of the African
virus even at the highest mAb concentration tested. We note
that the binding and neutralization activity to all ZIKV and
DENV strains increased during somatic evolution of the ZIKV-
116 lineage (Fig. 6, E and F). Further, the increased neutralization
potency of the affinity-matured mAb relative to the germline
configuration is highly correlated for each virus with the
monotypic binding affinity we measured for DIII (Fig. 6 G).
The ZIKV-116 epitope is not fully exposed in the cryo-EM
model of mature ZIKV
Three cryo-EM structures of mature ZIKV H/PF/2013 have been
reported to date (Sirohi et al., 2016; Kostyuchenko et al., 2016;
Sevvana et al., 2018), and we used the highest-resolution model
to evaluate how ZIKV-116might interact with the virion (Protein
Data Bank [PDB] 6CO8). Analysis of the virion structure in-
dicates that the DIII-LR epitope is predominantly solvent ex-
posed, with the exception of some parts of the CC9-loop (Fig. 7 A).
However, docking of our ZIKV-116-DIII complex to all three
unique T = 3 environments on the virus revealed that steric
Figure 5. Variation at residue 204 in DII is responsible for the neutralization difference between two DENV1 strains. (A) Cartoon of DENV1 E protein
(DI, red; DII, yellow; DIII, blue). ZIKV-116 epitope is highlighted in magenta. Amino acid differences (339 and 345) between 16007 andWest Pac-74 (WP) DIII are
shown in cyan. Residue 204, which is responsible for the difference in neutralization between two DENV1 strains, is marked as a black triangle in DII. (B and C)
Comparison of KD and t1/2 of ZIKV-116 to DIII from H/PF/2013, 16007, and West Pac-74. The results from at least two independent experiments are shown.
Error bars represent SD. (D–F) Effects of residue 204 on ZIKV-116 neutralization of DENV1 strains 16007 and West Pac-74. Neutralization profiles of mAbs
against WT DENV1 strains 16007 and West Pac-74 RVPs compared with mutant RVPs containing reciprocal amino acid at residue 204 (upper). IC50 values are
from three independent experiments (bottom). DENV1-E111, which was reported to display differential neutralization against DENV1 genotypes, is used as a
positive control mAb, andWNV-E60 serves as a negative control mAb. Statistical significance was determined by one-way ANOVA with a Tukey’s test (B and C)
or two-tailed t tests (D–F). ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001. FP, H/PF/2013.
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hindrance imposed by adjacent E subunits would cause clashes
with the ZIKV-116 VH domain (Fig. 7, B–D). Thus, the ZIKV-116
epitope can be considered to be partially cryptic in the context of
the mature, icosahedrally averaged structure. In fact, the
predicted virion binding orientation of ZIKV-116 places the Fab
lying nearly parallel to the virus membrane, similar to a typical
CC9-loop engaging mAb (i.e., DENV1-E111; Austin et al., 2012) and
in contrast to some other DIII-LR mAbs, which project away
Figure 6. ZIKV-116-V.J.Rev has reduced affinity and neutralization potency to ZIKV and DENV1. (A) Ribbon diagrams of variable region of ZIKV-116 mAb,
with the backbone of contacts highlighted in pink for light chain variable domain (VL) and magenta for VH. Somatic mutation residues are colored in green. The
substituted residues that are involved with DIII contacts are drawn as sticks. (B) Amino acid sequence alignment of the VH and VL of ZIKV-116 to its V-J reverted
germline genes. Somatic mutations are shaded as in A. Residues marked by magenta/pink symbols below the sequence show amino acids engaged in the
interface with DIII. (C) Analysis of the binding of ZIKV-116-V.J.Rev to DIII from ZIKV H/PF/2013, ZIKV MR-766, DENV1 16007, and DENV1 West Pac-74 as
measured by BLI. The experimental curves (black lines) were fitted using a 1:1 Langmuir binding analysis (red lines), and the results are representative of two or
three independent experiments. (D)Neutralization profiles of ZIKV-116 and ZIKV-116-V.J.Rev against indicated ZIKV and DENV1 strains as assessed by FRNT on
Vero cells. The data are pooled results from at least three independent experiments performed in triplicate or quadruplicate. (E and F) IC50 values and KD (nM)
comparison between somatically mutated (ZIKV-116SM) and V-J reverted germline version (ZIKV-116-V.J.Rev). (G) Neutralization potency (IC50 values) of four
strains by ZIKV-116SM and ZIKV-116-V.J.Rev versus KD to DIII of ZIKV H/PF/2013, ZIKV MR-766, DENV1 16007, and DENV1 West Pac-74. FP, H/PF/2013; MR,
MR-766.
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from the virion surface (i.e., DENV1-E106; Edeling et al., 2014;
Fig. 7, E–G). We speculate that as claimed for other viruses (e.g.,
WNV, DENV, norovirus, HIV, and hepatitis C virus; Dowd et al.,
2011; Sukupolvi-Petty et al., 2013; Lindesmith et al., 2014; Keck
et al., 2016; Mengistu et al., 2015), dynamic motions or
“breathing” of virions might enable cryptic epitopes to become
transiently exposed, allowing for antibodies like ZIKV-116 to
bind and neutralize infection. Virion breathing and its effects on
epitope accessibility have been well studied with other flavivi-
ruses, and time-dependent increases in mAb neutralization have
been observed for mAbs that recognize cryptic epitopes (Austin
et al., 2012; Dowd et al., 2011; Li et al., 2018; Lok et al., 2008). To
experimentally address this issue, we evaluated the time and
temperature dependence of ZIKV-116 neutralization (Fig. S3).We
observed mildly enhanced ZIKV neutralization by ZIKV-116
following prolonged incubation times, although these changes do
not appear particularly temperature dependent.
Discussion
Previous studies have shown that antibody-mediated immune
responses against flaviviruses are protective (Nybakken et al.,
2005; Sapparapu et al., 2016; Shrestha et al., 2010; Fernandez
et al., 2018). The identification of the mechanisms of neutrali-
zation and key epitopes of potently neutralizing antibodies has
implications for antibody-based therapies and vaccine develop-
ment. Here, using structural and functional approaches, we
characterized a DIII-LR mAb that is commonly elicited in hu-
mans against ZIKV and found to cross-react with DENV1, and
determined the molecular basis of its inhibitory activities.
Figure 7. Epitope comparison of neutralizing DIII-specific mAbs against ZIKV and DENV1. (A) Mapping of the ZIKV-116 epitope onto the mature ZIKV
virion (PDB 6CO8). E proteins in three symmetries are colored in wheat (twofold; C), olive (threefold; A), and gray (fivefold; B). The ZIKV-116 epitope is colored
in magenta, and K209(ZIKV) correlating to R/K204(DENV1) is colored in red. (B–D) Docking of the ZIKV-116 Fab onto representative twofold (B), threefold (C), and
fivefold (D) sites. Clashes with adjacent E proteins were highlighted in cyan and indicated with arrows. (E) Docking of the ZIKV-116, DENV1-E106 (exposed
A-strand epitope), and DENV1-E111 (cryptic CC9-loop epitope) Fabs onto the M-E dimer of the mature virion. ZIKV-116 binding to the LR of DIII is located
between the positions of DENV1-E106 and DENV1-E111. (F) Ribbon diagrams of DIII, and epitopes recognized by mAbs are rendered as sticks. LR/A-strand
epitopes are colored in magenta, and CC9-loop epitope is colored in cyan. (G) Sequence alignment of ZIKV and DENV1 with highlighted antibody epitopes (same
coloring as in F). ZIKV-Z006 (PDB 5VIG), ZIKV-ZK2B10 (PDB 6JEP), ZIKV-ZV-67 (PDB 5KVG), DENV1-Z004 (PDB 5VIC), DENV1-E106 (PDB 4L5F), ZIKV-ZV-64
(PDB 5KVF), and DENV1-E111 (PDB 4FFY) were used for the analysis.
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Mechanism-of-action experiments showed that ZIKV-116
could efficiently block infection even after the virus has attached
to target cells. Indeed, ZIKV-116 could block viral fusion with cell
membranes using an in vitro assay. We and others have previ-
ously described DIII-LR mAbs against WNV (Thompson et al.,
2009), JEV (Fernandez et al., 2018), and ZIKV (Wang et al., 2019)
that are capable of blocking viral membrane fusion, and similar
mechanisms of action have been reported for flavivirus mAbs
against other epitopes (Gollins and Porterfield, 1986; Füzik et al.,
2018; Zhang et al., 2016; Vogt et al., 2009; Zhang et al., 2015;
Cockburn et al., 2012). Consistent with its ability to block fusion,
ZIKV-116 retained high affinity binding to DIII at an acidified
endosomal pH. Fusion inhibition may be a particularly impor-
tant neutralization mechanism for flavivirus mAbs since virions
can apparently enter target cells through multiple receptors and
entry pathways (Pokidysheva et al., 2006; Hamel et al., 2015;
Sirohi and Kuhn, 2017; Perera-Lecoin et al., 2013; Cruz-Oliveira
et al., 2015).
We found that the neutralization potency of ZIKV-116 to
different ZIKV strains is highly correlated with the identity of
residue 393 in the FG-loop of DIII. Using engineered reporter
viruses, we found that an E393D change in the Asian ZIKV
H/PF/2013 strain resulted in significantly diminished neutral-
ization, while the reciprocal D393E substitution in the African
ZIKV MR-766 strain dramatically improved neutralization.
These results support the idea that E393 is critical for optimal
ZIKV-116 engagement, and indeed, neutralization is highly
correlated with ZIKV DIII binding affinity and half-life. We
previously described E393 as a contact residue for a murine
mAb, ZV-67 (Zhao et al., 2016), which also engages the DIII-LR
epitope, albeit from a different orientation compared with
ZIKV-116. However, ZV-67 neutralized all examined ZIKV
strains equivalently, and activity is unperturbed by E393D
substitutions. The likely explanation for this disparity is that
E393 coordinates an elaborate hydrogen-bonding network at the
ZIKV-116 paratope–epitope interface while it is a minor player
in the murine mAb interface.
Our studies have revealed that ZIKV-116 can neutralize
DENV1, with higher potency measured for genotype 2 strain
16007 relative to genotype 4 strain West Pac-74. Quantitative
binding experiments showed that DIII from both viruses binds
ZIKV-116 equivalently. Similar differences in genotype-
dependent neutralization of DENV1 were observed for the mu-
rine mAb DENV1-E111, which primarily recognizes a cryptic DIII
CC9-loop epitope (Austin et al., 2012; Dowd et al., 2015). For
DENV1-E111 the genotype-dependent differences in neutraliza-
tion were found to be due in part to DII residue 204, which may
allosterically affect the display of DIII epitopes (Fig. 5 E; Dowd
et al., 2015). Here, we have found that residue 204 plays a
similar role in modulating ZIKV-116 neutralization sensitivity of
DENV1 strains, with R204-containing viruses better inhibited
than K204 viruses. Similar to DENV1-E111, our analysis suggests
that the DIII-LR epitope engaged by ZIKV-116 is cryptic. Indeed,
while the epitope is predominantly solvent exposed, docking of
our crystal structure onto cryo-EM models of mature viruses
indicated steric clashes of the Fab that could only be resolved by
envelope rearrangements. While it is tempting to speculate that
DENV1 residue 204 could play a role in such virion conforma-
tional dynamics, as it is located ∼60 Å away from the DIII-LR
epitope of the same E protein, it is formally possible that it is
instead a direct contact residue, as it is located only ∼30 Å dis-
tant by icosahedral symmetry (Fig. S4). The precise role of
residue 204 may be best addressed in future studies of virion-
antibody complexes using cryo-EM.
Human mAbs that target DIII and cross-react between ZIKV
and DENV1 have been described from at least eight donors ex-
amined by four independent groups (Robbiani et al., 2017;
Sapparapu et al., 2016; Magnani et al., 2017; Niu et al., 2019).
Remarkably, all of these mAbs use the same germline precursors
as ZIKV-116, specifically the VH3–23 heavy chain and VK1–5 light
chain, arguing strongly that this pairing represents a broadly
shared, public antibody lineage. Similar to ZIKV-116, many of
these VH3–23/VK1–5–derived mAbs exhibit better neutralization
of Asian ZIKV strains relative to African strains (Niu et al., 2019;
Magnani et al., 2017). Further, protection studies in macaques
with one of these mAbs, Z004, led to a viral escape mutant with
an E393D substitution (Keeffe et al., 2018), a result supporting
our conclusion that natural variation at residue 393 determines
the differential neutralization of ZIKV strains by ZIKV-116. In
recent years, germline-targeted vaccine development has been
explored for HIV, with immunogens engineered for optimal
engagement of broadly neutralizing mAb precursors (Jardine
et al., 2016; Steichen et al., 2016; Duan et al., 2018; Burton,
2019). We found that the V-J reverted germline form of ZIKV-
116 can broadly bind and neutralize ZIKV and DENV1 strains,
with the highest potency against Asian ZIKV strain H/PF/2013.
Thus, to induce VH3–23/VK1–5 lineage mAbs like ZIKV-116,
vaccine strategies should probably include ZIKV E proteins that
encode E393, although suboptimal protection against African
ZIKV strains is possible.
In summary, we have defined the structural and molecular
mechanism of a representative DIII-LR–specific mAb from a
common germline lineage in humans. We found that the po-
tency of ZIKV-116 against ZIKV strains is tightly correlated with
a single epitope residue that modulates binding affinity, while
differential DENV1 strain neutralization depends on a residue
outside the epitope, which presumably modulates epitope ac-
cessibility on the virion. These studies highlight how the choice
of virus strain can impact antibody responses and inform future
epitope-based and germline-directed vaccine strategies against
flavivirus infections.
Materials and methods
Key resources can be found in Table S9.
Viruses and cells
Vero, C6/36, and HEK 293T cells were maintained in DMEM
supplemented with 7% FBS, 100 U/ml penicillin/streptomycin,
10 mM Hepes, 1 mM sodium pyruvate, and 1× nonessential
amino acids. Raji cells (Raji-DCSIGNR) which express the at-
tachment factor DC-SIGNR (dendritic cell–specific ICAM-
3–grabbing nonintegrin related) were maintained in RPMI
1640 medium with the same media supplements.
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Virus and RVPs
ZIKV strains H/PF/2013 (French Polynesia, 2013) and MR-766
were grown in Vero cells at 37°C. DENV1 16007 (genotype 2) and
West Pac-74 (genotype 4) were amplified in C6/36 Aedes albo-
pictus cells at 28°C. ZIKV and DENV1 RVPs were generated as
described previously (Dowd et al., 2016, 2015). HEK 293T cells
were cotransfected with a plasmid encoding the structural
C-prM-E proteins and another plasmid encoding a WNV repli-
con with a GFP reporter gene, which can be used to monitor
infection by flow cytometry. RVP-containing supernatants were
harvested between 72 and 120 h after transfection and frozen at
−80°C.
Focus-forming and reduction assays
A focus-forming assay (FFA) was used to determine virus titer
on Vero cells. Vero cell monolayers were inoculated with virus
or virus-mAb mixture and incubated at 37°C for 1 h. Cells then
were overlaid with 1% (wt/vol) methylcellulose in MEM sup-
plemented with 4% FBS and incubated at 37°C. 40 h (ZIKV) or
68 h (DENV) later, the cells were fixed with 4% paraformalde-
hyde and incubated with 500 ng/ml WNV-E60 mAb (Oliphant
et al., 2006) in PBS buffer supplemented with 0.1% saponin and
0.02% Tween 20 for 2 h. After washing, cells were stained with
HRP-conjugated goat anti-mouse IgG, and virus-infected foci
were developed using TrueBlue peroxidase substrate (KPL) for
30 min and counted by an ImmunoSpot 5.0.37 macroanalyzer
(Cellular Technologies).
Focus reduction neutralization tests (FRNT) were conducted
with indicated ZIKV strains and mAbs in Vero cells in 96-well
plates as described previously (Zhao et al., 2016). The infection
frequency of the wells inoculated with virus in the presence of
mAb was compared with that of wells inoculated with virus and
medium alone. The IC50 values were determined using nonlin-
ear regression analysis (GraphPad Prism).
RVP titration and neutralization assay
ZIKV and DENV1 RVP neutralization assays were performed as
previously described (Dowd et al., 2016, 2015). To determine
virus titer, twofold dilutions of RVPs were used to infect Raji-
DCSIGNR in duplicate technical replicates at 37°C. GFP-positive
infected cells were detected by flow cytometry 40 h later. In
subsequent neutralization assays, RVPs were sufficiently diluted
to within the linear range of the virus-infectivity dose-response
curve to ensure antibody excess at informative points. To
measure neutralization, ZIKV or DENV1 RVPs were mixed with
serial dilutions of mAb for 1 h at 37°C, followed by infection of
Raji-DCSIGNR cells in duplicate technical replicates. Infections
were performed at 37°C, and GFP-positive infected cells were
quantified by flow cytometry 2 d later. Results were analyzed by
nonlinear regression analysis to estimate the dilution of mAb
required to inhibit 50% of infection (IC50).
ELISA
All the recombinant E and DIII (5 µg/ml) from distinct flavivi-
ruses were coated onto a MAXISORP 96-well plate (Nunc) and
blocked with PBS supplemented with 0.02% Tween 20, 5% BSA,
and 5% goat serum. 1 h later, plates were incubated with ZIKV-
116 or control mAbs (WNV-E111 [Oliphant et al., 2006], DENV4-
E88 [Sukupolvi-Petty et al., 2013], JEV-106 [Fernandez et al.,
2018], and POWV-61 [unpublished mAb]), followed by HRP-
conjugated anti-human or anti-mouse IgG (sc-2907 or sc-2005;
Santa Cruz Biotechnology). The reaction was developed with
3,39-5,59 tetramethylbenzidine substrate followed by stopping
with the addition of 1 N H2SO4, and the absorbance was mea-
sured at 450 nm.
Protein production, purification, and crystallization
ZIKV DIII (H/PF/2013 and MR-766, residues 299–407), DENV1-4
DIII (residues 293–399; Austin et al., 2012), WNV DIII and E
(New York, 1999; residues 296–401 [DIII] and residues 1–406 [E];
Luca et al., 2012; Nybakken et al., 2005), JEV DIII (SA14-14-2,
residues 299–399; Fernandez et al., 2018), POWV DIII (Spooner,
residues 298–399), ZIKV E (H/PF/2013, residues 1–407), and
SPOV E (SM6 V-1, residues 1–411) were cloned into the pET21a
vector (Novagen) and expressed as inclusion bodies in Esche-
richia coli BL21(DE3). Isolated inclusion bodies were solubilized
and refolded as previously described (Dai et al., 2016; Nybakken
et al., 2005). ZIKV-116 heavy and light chain variable regions
were codon-optimized for mammalian expression and synthe-
sized on a BioXP 3200 DNA synthesis instrument (SGI-DNA).
The resulting gene fragments were cloned directly into CMV-
driven mammalian expression vectors that had already been
fused with CH1-2-3 for IgG1, CH1 for Fab, and CK for IgK. ThemAb
or Fab heavy and light chain vectors were cotransfected into
Expi293F or ExpiCHO cells (Thermo Fisher) for transient ex-
pression. After 7 d of culture, the culture supernatants were
separated by centrifugation, filtered, and purified by fast protein
liquid chromatography on an ÄKTA instrument using a HiTrap
MabSelect Sure column (GE Healthcare) or a CaptureSelect IgG-
CH1 column (Thermo Fisher), respectively. The purified mAb or
Fab then was buffer-exchanged into PBS.
Purified ZIKV-116 Fab was incubated with excess DIII for 2 h
followed by complex isolation through size exclusion chroma-
tography (Superdex 75 16/600). The complexes were collected
and crystallized in hanging drops at 20°C. Diffraction quality
crystals were obtained in the condition of 30% 2-Methyl-2,4-
pentanediol, 0.1 M imidazole, and 10% polyethylene glycol 4K, at
a concentration of 12 mg/ml. Protein crystals were cryo-
protected in reservoir solution with 15% ethylene glycol before
being flash-cooled in liquid nitrogen.
Structure determination and refinement
Diffraction data were collected at the Advanced Photon Source
beamline 24-ID-C and processed with the HKL2000 program.
Structural phase was determined by molecular replacement in
Phenix (Adams et al., 2010) using the Phaser GUI (McCoy et al.,
2007), and previously solved ZIKV DIII from the complex of ZV-
67-DIII (PDB 5KVG) and human Fab structure from Z20-sE (PDB
5GZO) were used as the search models, respectively. Cycles of
model building and refinement were performed in Coot (Emsley
et al., 2010) and Phenix. The structural figures were generated
in PyMOL software. The interaction of Fab and DIII was ana-
lyzed in the ligplot program suite using default settings
(McDonald and Thornton, 1994). The buried surfaces and shape
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complementarity were calculated using PISA (http://www.ebi.
ac.uk/msd-srv/prot_int/).
BLI
The binding affinity of recombinant DIII with ZIKV-116 was
monitored by BLI using an Octet-Red96 device (Pall ForteBio).
ZIKV-116 and ZIKV-116-V.J.Rev mAbs were biotinylated using
EZ-Link-NHS-PEG4-Biotin reagent and then loaded onto strep-
tavidin biosensors (ForteBio). Binding at neutral pH was deter-
mined in HBS-EP buffer (10 mM Hepes, pH 7.4, 150 mM NaCl,
3 mM EDTA, 0.005% P20, and 3% BSA). Low pH binding was
performed in a similar assay buffer with the pH adjusted to 5.5
using 2-ethanesulfonic acid buffer. Buffer alone with loaded
mAb and sensor alone with the highest concentration of DIII
were added in parallel to serve as negative controls. The ex-
perimental curves were analyzed using Biaevaluation 4.1 (GE
Healthcare) and fitted by a 1:1 Langmuir fitting model to deter-
mine the associate constant (ka), dissociate constant (kd), kinetic
binding affinity (KD, kinetic), and steady-state affinity (KD,
equilibrium).
Attachment inhibition assay
Attachment blockade was measured by qRT-PCR on an ABI 7500
Real Time-PCR system (Applied Biosystems). 2 × 105 Vero cells
were seeded in 24-well plates and incubated for 24 h. ZIKV (2 ×
102 focus-forming units [FFU]) were preincubated with ZIKV-
116 or a human isotype control (anti-influenza IgG1) mAb (0.1
µg/ml, 1 µg/ml, 10 µg/ml) for 1 h, followed by addition of the
mAb-virus complex to chilled Vero cells for 1 h at 4°C. Cells were
extensively washed with cold DMEM on ice, and total RNA was
extracted using an RNeasy Mini Kit (Qiagen). ZIKV RNA levels
were determined using a Taqman RNA-to-Ct 1-Step Kit (Thermo
Fisher) normalized to the internal control GAPDH. Primers and
probes used are as follows: ZIKV-E-Fwd, 59-CCACCAATGTTC
TCTTGCAGACATATTG-39; ZIKV-E-Rev, 59-TTCGGACAGCCG
TTGTCCAACACAAG-39; Probe ZIKV-E, 56-FAM/AGCCTACCT/
ZEN/TGACAAGCAGTC/3IABkFQ; GAPDH-Fwd, 59-TGTAGTTGA
GGTCAATGAAGGG-39; GAPDH-Rev, 59-ACATCGCTCAGACAC
CATG-39; Probe GAPDH, 56-FAM/AAGGTCGGA/ZEN/GTCAAC
GGATTTGGTC/3IABkFQ.
Pre- and post-attachment neutralization assays
For the pre-attachment inhibition assay, serial dilutions of ZIKV-
116 were incubated with ZIKV (102 FFU) for 1 h at 4°C followed by
addition to chilled Vero cells for 1 h. The cells were washed three
times with cold DMEM to remove unbound virus, then the plates
were transferred to 37°C, and standard FFAs were performed as
described above. For post-attachment inhibition assay, 102 FFU
of ZIKV was inoculated onto chilled Vero cells for 1 h at 4°C, and
then cells were washed with cold media to remove unbound
virus, followed by the addition of serial dilutions of ZIKV-116 for
1 h at 4°C. Finally, excess mAbs were washed away, and standard
FFAs were conducted as described above.
Plasma membrane fusion assay
Vero cells seeded in 96-well plates were rinsed once with PBS
and then incubated with DMEM supplemented with 25 mM
NH4Cl and 0.2% BSA (DMEM-NH4Cl) on ice for 15 min. ZIKV
(multiplicity of infection of 80) was added to cells for 1 h at 4°C
followed by three washes with chilled DMEM-NH4Cl to remove
unbound virus. The cells were incubated with 100 µg/ml of
mAbs or media without mAb for 1 h on ice. After washing with
chilled DMEM-NH4Cl, cells were incubated with acidic medium
(~pH 5.8) or neutral medium (pH 7.4) for 9 min at 37°C to induce
viral fusion with cell membrane. Subsequently, cells were
washed with DMEM-NH4Cl (pH 7.4) and incubated at 37°C with
DMEM containing 25 mM NH4Cl to prevent endosomal-
mediated viral fusion and secondary infection. The cells were
fixed with 2% paraformaldehyde 24 h after infection and se-
quentially incubated with the cross-reactive WNV-E53 mAb
(Oliphant et al., 2006; 0.5 µg/ml; recognize E protein) and goat
anti-mouse PE-conjugated antibody (1:1,000). Finally, the cells
were washed three times and subjected to flow cytometry
analysis, and data were analyzed using FlowJo software.
Statistical analysis
All functional results were analyzed using GraphPad Prism
Software, and differences were evaluated by two-tailed t test or
ANOVA test with post hoc corrections for multiple comparisons.
A P value of <0.05 was considered to be significant.
Data availability
The atomic coordinates of ZIKV-116 Fab in complex with ZIKV
DIII have been submitted to the RCSB PDB with accession
no. 6PLK.
Online supplemental material
Fig. S1 shows that there are two ZIKV-116–DIII complexes in a
crystallographic asymmetric unit, which is related to Fig. 2. Fig.
S2 shows amino acid differences in DIII between two repre-
sentative ZIKV strains (H/PF/2013 and MR-766) and two DENV1
strains (16007 and West Pac-74), which is related to Fig. 5. Fig.
S3 shows time- and temperature-dependent neutralization
curves for ZIKV-116 against ZIKV strain H/PF/2013. Fig. S4
shows the distance of residue 393 within structural ZIKV-116
epitope to residue 204DENV1/209ZIKV from the same E protein or
adjacent E protein on the virion surface. Table S1 presents
crystallographic data collection and refinement statistics. Tables
S2 and S3 provide van der Waals contacts for ZIKV-116–DIII
complex. Tables S4–S6 present hydrogen bond contacts between
ZIKV-116 and DIII. Table S7 shows the neutralizing values of
ZIKV-116 and ZV-67 against different ZIKV strains. Table S8
provides binding parameters for ZIKV-116 to recombinant DIII
protein of distinct ZIKV and DENV1 strains measured by BLI.
Table S9 shows key resource information used in this study.
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